Clinical Trials in New York State

Showing 6221-6240 of 17,167 trials

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

NCT04040894

This is an expanded access protocol intended to provide access to teprotumumab for the treatment of up to 60 patients in the United States with active moderate to severe thyroid eye disease where there is no comparable or satisfactory alternative therapy for treatment.

Thyroid Eye DiseaseGraves' Orbitopathy

Amgen

Beverly Hills, California, United States • Miami, Florida, United States • Skokie, Illinois, United States +5 more locations

TERMINATEDPhase 1107 miles

Phase I/II Study of Avelumab in Pediatric Cancer Participants

NCT03451825

This is a multi-center, open-label, international study to evaluate the dose, safety and tolerability, antitumor activity, pharmacokinetic and pharmacodynamics of avelumab in pediatric subjects 0 to less than 18 years of age with refractory or relapsed malignant solid tumors (including central nervous system tumors) and lymphoma for which no standard therapy is available or for which the subject is not eligible for the existing therapy. The study was planned to be conducted in 2 parts: the dose-finding part (Phase I) and the tumor-specified expansion part (Phase II). However, Phase II was cancelled due to limited clinical benefit of PD-L1 monotherapy in pediatric participants.

Refractory or Relapsed Solid TumorsLymphoma

EMD Serono Research & Development Institute, Inc.21 participantsStarted Mar 2018

Aurora, Colorado, United States • The Bronx, New York, United States • Brussels, Belgium +8 more locations

Expanded Access Protocol of Teprotumumab (HZN-001) for Patients With Active Thyroid Eye Disease

Phase I/II Study of Avelumab in Pediatric Cancer Participants

Find Trials by Condition in New York State

Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer

Open-Label Study of Oral Treprostinil in Digital Ulcers

An Extension Study of KRN23 in Adults With X-Linked Hypophosphatemia

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Treatment of Tendinosis Using the TenJet Hydroresection System

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Canadian National PDA Treatment Study

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa

Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction

Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies